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Features of the QRS complex of the electrocardiogram, reflecting ventricular depolarisation,
associate with various physiologic functions and several pathologic conditions. We test 32.5
million variants for association with ten measures of the QRS complex in 12 leads, using
405,732 electrocardiograms from 81,192 Icelanders. We identify 190 associations at 130 loci,
the majority of which have not been reported before, including associations with 21 rare or
low-frequency coding variants. Assessment of genes expressed in the heart yields an addi-
tional 13 rare QRS coding variants at 12 loci. We find 51 unreported associations between the
QRS variants and echocardiographic traits and cardiovascular diseases, including atrial
fibrillation, complete AV block, heart failure and supraventricular tachycardia. We demon-
strate the advantage of in-depth analysis of the QRS complex in conjunction with other
cardiovascular phenotypes to enhance our understanding of the genetic basis of myocardial
mass, cardiac conduction and disease.
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The QRS complex (Fig. 1) of the electrocardiogram (ECG) isa summation of electrical activity in the heart duringventricular depolarisation. It represents electrical activation
of the left and right ventricles of the heart, propagated through
the specialised conduction system1, which includes the His
bundle, right and left bundle branches and the Purkinje network.
Normal ventricular depolarisation is a rapid process activating
different ventricular myocardial segments in a precise temporal
sequence, resulting in a narrow QRS complex with a character-
istic pattern on the 12-lead ECG1. Deviation from the norm has
been associated with sudden cardiac arrest (prolonged ventricular
activation time)2,3 and mortality in the general population
(prolonged QRS duration)4 and among individuals free of car-
diovascular disease (low QRS voltage)5.
Many traits and diseases affect the morphology of the QRS
complex, including body habitus, primary conduction abnorm-
alities, hypertrophy and dilatation of the ventricles, myocardial
infarction, pericardial effusion and lung disease6. Measures of the
QRS complex have been used as prognostic indicators and mar-
kers of heart disease severity, such as heart failure7, ventricular
hypertrophy8 and amyloidosis9.
Prior genome-wide association studies (GWAS) of the QRS
complex were limited to testing QRS duration and voltage criteria
reflecting left ventricular hypertrophy, yielding sequence variants
at 58 loci with minor allele frequency (MAF) >4%10–15.
To gain a better understanding of the molecular mechanism of
ventricular conduction, we perform a large GWAS of ten mea-
sures of the QRS complex in 12 leads from ECGs of 81,192
individuals. These ten measures are the Q, R and S wave ampli-
tudes and durations, QRS complex area and duration, ventricular
activation time, and the distance from the peak of the R wave to
the nadir of the S wave (QRS p-2-p). We analyse each measure for
12 ECG leads: limb leads (I–III), augmented limb leads (aVR,
aVL, aVF) and precordial leads (V1–V6). We also analyse three
other parameters: mean QRS duration over 12 leads, the Cornell
voltage criterion and the Sokolow-Lyon voltage criterion. In total,
we analyse 123 QRS complex parameters and this results in the
identification of 190 associations between the QRS complex and
variants at 130 loci, for which we further assess effects on seven
echocardiographic traits and 22 cardiovascular diseases. We
demonstrate the advantage of analysing 12 leads of the ECG and
identify rare protein-coding variants in genes that can improve
the understanding of risk and progression of heart disease and
help direct future studies.
Results
QRS associations. We performed a GWAS on 81,192 indivi-
duals, testing 32.5 million common and rare (MAF > 0.01%)
SNPs and indels for association with 123 QRS complex para-
meters (Supplementary Fig. 1, Supplementary Tables 1 and 2).
The variants were identified by whole-genome sequencing
15,220 Icelanders and imputed into 151,677 long-range phased
individuals and their relatives16. We adjusted the threshold for
genome-wide significance with a weighted Bonferroni proce-
dure, using as weights the predicted functional impact of
association signals17 (Supplementary Table 3). Sequence var-
iants at 130 loci (MAF > 0.1%) associate with at least one QRS
complex parameter. Using conditional analysis, we identified
60 secondary signals at 32 of the loci, resulting in 190 distinct
associations (Supplementary Data 1 and 2). We replicated
associations at all 54 reported QRS loci with at least one of the
123 QRS parameters (Supplementary Data 3, Supplementary
Table 4; P < 0.05/123= 4.1 × 10−4).
Among the 190 variants that associate with QRS parameters,
159 are common (MAF > 5%) with effects ranging in magnitude
from 0.04 to 0.14 standard deviations (s.d.), 14 are low-frequency
(1% <MAF ≤ 5%) with effects ranging from 0.11 to 0.35 s.d., and
17 are rare (MAF ≤ 1%) with effects ranging from 0.19 to 1.9 s.d.
We found genome-wide significant associations with 115 of
123 QRS parameters tested. There were no genome-wide
significant associations with eight Q wave amplitude and duration
parameters, of which four had relatively few available measure-
ments (N < 15,000). Of the 190 variants, 160 associate genome-
wide significantly with more than one QRS parameter. The R
amplitude is the QRS measure that captures the most associations
(N= 96), followed by QRS area (N= 85) and R duration (N=
76), while the Cornell voltage criterion captures the fewest (N=
18) (Supplementary Fig. 2). Some of the variants associate only
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Fig. 1 ECG wave and the QRS complex. We denote QRS measures used in the analysis with grey lines. We illustrate the different viewpoints of the 12 ECG
leads in the upper-right corner. Amp. amplitude, Dur. duration, VAT ventricular activation time
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(N= 9), QRS area (N= 5), QRS p-2-p (N= 4) or ventricular
activation time (N= 4).
For the R amplitude, we identified most associations with lead
V1 (N= 47, Fig. 2). Fifteen variants associate only with the R
amplitude in lead V1. We identified more than twice as many
associations for the QRS p-2-p amplitude in lead aVR than in any
other lead (N= 47). For the QRS area, we identified most
associations with lead II (N= 43); with lead V3 for QRS duration
(N= 39); with lead V5 for R duration (N= 33), S duration (N=
33) and S amplitude (N= 31); and with lead V6 for ventricular
activation time (N= 28), Q amplitude (N= 24) and Q duration
(N= 9). Across all QRS measures, we observed the fewest
associations with leads III and aVL.
The genes harbouring the missense and loss-of-function
variant associations likely encode proteins that play roles in the
biology of the QRS complex. Variants annotated as coding/splice
represent 47 of the 190 QRS associations, of which 28 are at
unreported QRS loci—14 rare and 7 low frequency (Supplemen-
tary Data 1 and 2). Loss-of-function variants in HMCN2 and
SH3BGR associate most significantly with the QRS p-2-p
amplitude, in MYBPC3 and TTN with R wave duration and
SCN5A with QRS duration. MYBPC3, TTN and SCN5A are
established cardiac disease genes, but SH3BGR and HMCN2 are
not. Of the missense variants, 20 associate most significantly with
the R amplitude (in ADAMTS7, ALPK3, BAG3, CASP7,
CCDC141, CILP, DERL3, FHOD3, FLNC, MYH6, MYH7,
MYH7B, MYO18B, NACA, PLEC, RYR2, STAB1 and TTN), 4
with the QRS area (in ALDH1A2, RBM20 and TTN) and 4 with
the QRS p-2-p amplitude (in CAND2, HMCN2, SENP2 and
STON1-GTF2A1L). Twelve variants associate most significantly
with other QRS parameters (in ADAMTS6, ADPRHL1, C17orf58,
CCDC141, CFAP46, KLHL38, LAMA3, MAPT, PLCE1, SCN10A,
SYNPO2L and TTN).
We tested the 190 QRS variants for association with the
ventricular conduction disorders, left anterior/posterior fasci-
cular block (LAFB/LPFB) and left/right bundle branch block
(LBBB/RBBB). Using a 5% false discovery rate (FDR, P ≤ 0.003),
we observed 46 associations with 37 variants (Supplementary
Data 4). Three variants associate genome-wide significantly
with LAFB, including the missense variant p.Leu294Arg
(MAF= 4.4%) in ADPRHL1 (OR= 1.37, P= 4.8 × 10−8), cod-
ing for a cardiac-restricted protein essential for heart chamber
outgrowth18. The stop-gain variant p.Ser699Ter in HMCN2
(MAF= 2.0%) associates with a high risk of LPFB (OR= 2.31,
P= 5.2 × 10−4).
To assess the genetic relationship between ventricular
depolarisation and other electrical functions of the cardiac
conduction system, we tested the genetic correlation between
different ECG measures. The genetic correlation (Methods)
between mean QRS duration and mean PR interval duration is
0.14 (95% CI: 0.06–0.21) and between mean QRS duration and
mean QT interval duration is 0.31 (95% CI: 0.23-0.40). We also
tested the 190 QRS variants for association with ECG measures
reflecting atrial and atrioventricular conduction (P–Q compo-
nent of the ECG), and ventricular repolarisation (ST–T
component) (Supplementary Fig. 3, Supplementary Data 5).
Using a 5% FDR (P ≤ 0.016), 177 of the variants associate with a
non-QRS measure of the ECG. Of those, 16 have more
significant effects on non-QRS components: the PR interval
(at CAV1, OBFC1, SCN5A, SCN10A and TBX3), T amplitude (at
KLF12, LMF1, MYBPC3 and RNF207), P amplitude (at
SYNPO2L and MYH6) and ST duration (at MYH7B and
RNF207). The pattern of magnitude and direction of effects
associated with different ECG parameters is highly variable
between variants.
Replication. We assessed the associations of unreported QRS
variants in (1) QRS parameters similar to ours from 19,885 ECGs
of participants in the UK Biobank and (2) a published GWAS14
on four QRS measures from up to 73,518 participants.
Using data from the published GWAS on QRS duration and
three voltage criteria14, we tested variants that associated genome-
wide significantly in the Icelandic material with any of these four
parameters. We tested seven variants and all replicated (P < 0.05
and the same direction of effects, Supplementary Data 6). In the
smaller UK Biobank data, we tested variants that we expected to
replicate (over 99% power). Of 13 variants tested, all had the same
direction of effects in both datasets and 11 replicated (P < 0.05
and the same direction of effects, Supplementary Data 7).
Associations with echocardiographic traits. Using echocardio-
grams of 21,275 Icelanders, we tested the QRS variants for asso-
ciation with 7 echocardiographic left ventricular measurements
(Supplementary Table 5, Supplementary Data 8). We observed 23
associations with 18 variants (Table 1, 5% FDR, P ≤ 7.1 × 10−4),
most with the left ventricular end-diastolic diameter (LVEDD). The
splice-acceptor site mutation c.927-2 A >G in MYBPC3, known to
cause familial hypertrophic cardiomyopathy19, associates with
interventricular septum thickness (β= 1.2 s.d., P= 1.5 × 10−37), left
ventricular posterior wall thickness and LVEDD. The missense
variant p.Cys151Arg in BAG3, known to associate with heart failure
due to dilated cardiomyopathy20, associates with LVEDD (β=
−0.10 s.d., P= 1.8 × 10−13). We discovered ten unreported asso-
ciations, including an association with rs4794562[T] intronic to
HLF, encoding a circadian PAR bZip transcription factor21, and
LVEDD (β=−0.06 s.d., P= 5.3 × 10−6).
Associations with cardiovascular diseases. The 190 QRS variants
are a priori more likely to associate with cardiovascular diseases
than random sequence variants, and thus we tested them for
association with 22 cardiovascular diseases in Icelandic datasets,
including cardiac arrhythmias, cardiomyopathy and coronary
artery disease (CAD). For 18 of the diseases, we also had data
from the UK Biobank22 and performed a meta-analysis (Sup-
plementary Table 6, Supplementary Data 9).
Two rare QRS variants associate with several cardiovascular
dysfunctions. C.927-2A>G in MYBPC3 (MAF= 0.18%) associ-
ates with cardiomyopathy, heart failure, ventricular tachycardia
and atrial fibrillation (AF), and p.Arg721Trp (MAF= 0.34%) in
MYH6 with sick sinus syndrome (SSS), AF and coarctation of the
aorta. We have previously reported the effects of these variants on
risk and progression of heart diseases, as well as two other QRS
variants at PLEC and PALMD19,23–26. Excluding these four
variants, we observed 91 associations with 57 of the remaining
QRS variants (5% FDR, P ≤ 1.0 × 10−3). Most of the associations
are with AF (N= 30), essential hypertension (N= 11), CAD
(N= 10) and myocardial infarction (N= 10), of which many
have been reported27–34. We also identified reported associations
with dilated cardiomyopathy and heart failure20, SSS and
presence of pacemaker10.
We found 41 unreported associations with 32 variants and 16
cardiovascular traits (Table 2). Notably, the intronic variant
rs11166990[A] in PXN, which associates with the R amplitude in
lead V1, associates with reduced risk of AF (MAF= 1.3%, OR=
0.82, P= 4.0 × 10−8). Paxillin, encoded by PXN, is expressed at
focal adhesions of non-striated cells and costameres of striated
muscle cells35. Rs11166990[A] upstream of PTK2 (coding for focal
adhesion kinase), which also associates with the R amplitude in
lead V1, associates with hypertension (MAF= 48%, OR= 0.97, P
= 1.1 × 10−6), aortic valve stenosis (OR= 0.92, P= 2.1 × 10−4),
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Fig. 2 Intersection plots of associations for the QRS measures. In each panel, the left bar plot shows how many of the 190 QRS variants associate (P < 5 ×
10−8) with each lead. The top bar plot shows the sizes of intersecting sets of associations for the leads denoted with (connected) black dots. a Q
amplitude; b Q duration; c Ventricular activation time; d R amplitude; e S amplitude; f R duration; g S duration; h QRS area; i QRS duration; j QRS peak-to-
peak
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and is known to associate with reduced risk of AF. The rare
missense variant p.Ala2397Val in FLNC (MAF= 0.13%), which
associates with a larger R amplitude in lead V1, reduces the risk of
myocardial infarction (OR= 0.42, P= 1.3 × 10−4) and delays its
onset (β= 0.78 s.d., P= 1.1 × 10−4), with greater protection
against myocardial infarction in individuals younger than 76
years (OR= 0.21, P= 3.8 × 10−6). Variants in FLNC are known to
cause cardiomyopathy, and we recently reported the frameshift
variant p.Phe1626Serfs*40 in FLNC36 with opposite direction of
effects on the R amplitude in lead V1 and myocardial infarction to
those of p.Ala2397Val (Supplementary Table 7).
We found four unreported associations with supraventricular
tachycardia (SVT), represented by rs75013985[G] intronic to
KCND3 (AF= 2.2%, OR= 1.61, P= 2.7 × 10−9); rs629234[T]
upstream of PRRX1 (MAF= 47.9%, OR= 1.11, P= 8.6 × 10−6),
which also associates with AF and CAD; rs12144451[C] in
CASQ2 (MAF= 43.1%, OR= 0.92, P= 4.4 × 10−4), which also
associates with AF; and the missense variant p.Arg935Trp in
CCDC141 (MAF= 11.7%, OR= 1.14, P= 7.9 × 10−4). We found
three associations with complete AV block (CAVB), represented
by p.Glu382Asp in CCDC141 (MAF= 15.3%, OR= 1.29, P=
3.6 × 10−7), which also associates with pacemaker insertion
(OR= 1.12, P= 5.9 × 10−5) and SSS (OR= 1.13, P= 2.1 × 10−4);
rs4794562[T] intronic to HLF (MAF= 25.7%, OR= 0.86, P=
7.8 × 10−4), which also associates with heart failure (OR= 0.95,
P= 6.7 × 10−5); and rs17226667[A] near CEP85L (MAF= 45.8%,
OR= 1.13, P= 8.1 × 10−4). We found three unreported associa-
tions with dilated cardiomyopathy, represented by the missense
variant p.Val77Ala in CAND2 (MAF= 32.7%, OR= 0.82, P=
3.9 × 10−5), rs35006907[A] near ZNF572 (MAF= 35.8%, OR=
0.82, P= 7.0 × 10−5), and rs10838681[A] upstream of NR1H3
(MAF= 31.8%, OR= 1.19, P= 3.1 × 10−4).
Some of the QRS variants that associate with AF have effects
on non-QRS components of the ECG, mainly the P amplitude
and the PR interval, measuring atrial and atrioventricular nodal
conduction (Supplementary Fig. 3). We tested these QRS variants
in a subset of our data containing 236,896 ECGs in sinus rhythm
of 57,399 individuals without AF. Most variants still had the
strongest effects on the QRS complex and non-significant effects
on the P amplitude (5% FDR), indicating that the QRS effect is
not a consequence of the arrhythmia (Supplementary Fig. 4).
Parent-of-origin effects. We tested the 190 QRS variants for a
difference in effects under maternal and paternal models of
transmission (Supplementary Table 8)37. Two variants have more
than three times greater effect when inherited paternally than
maternally (Table 3, P < 0.05/190= 2.6 × 10−4). One is
rs11761424[A] (MAF= 35%) intronic to DGKB (encoding a
diacylglycerol kinase), which associates most significantly with R
wave duration in lead V4 (βpat= 0.068 s.d., βmat= 0.018 s.d.,
Phet= 4.1 × 10−5). Sequence variants near DGKB are known to
associate with type 2 diabetes38 and AF27 but do not correlate
with rs11761424 (r2 < 0.01). The other is rs116904997[A]
(MAF= 1.3%) intronic to PXN (encoding paxillin), which
associates most significantly with the R amplitude in lead V1
(βpat= 0.28 s.d., βmat= 0.073 s.d., Phet= 1.6 × 10−4). Paxillin is a
cytoskeletal protein involved in actin-membrane attachment at
sites of focal adhesion35. In the Genotype-Tissue Expression
(GTEx) dataset39, rs116904997[A] associates more significantly
than any other variant with the expression of PXN in the left
ventricle of the heart (Supplementary Fig. 5, P= 3.0 × 10−9).
These loci are not known to be imprinted.
Pathway analysis. We applied the data-driven expression-priori-
tised integration for complex traits (DEPICT, Methods)40 to
search for tissues and cell types in which our variants are more
likely to be expressed. Enrichment testing of expression in 209
tissues and cell types pointed out cardiovascular tissue (atria,
ventricles and arteries) as well as the myometrium and muscles
(1% FDR, Supplementary Data 10). Furthermore, DEPICT iden-
tified 495 enriched gene sets out of 14,461 reconstituted gene sets
Table 1 Associations between the QRS variants and echocardiographic traits
Trait Variant Chr. Pos. (hg38) EA/OA EAF (%) Locus Annotation Top QRS parameter Effect (s.d.) P
ARD rs11874 17 46,939,827 A/G 12.9 GOSR2 3′ UTR S dur., V4 0.11 8.0 × 10−9
ARD rs7543039 1 99,584,092 C/T 48.8 PALMD Intergenic S amp., V4 −0.064 1.5 × 10−8
ARD rs2687938 13 50,180,110 T/C 45.6 DLEU1 Intergenic QRS area, V4 0.057 4.6 × 10−7
ARD rs335196 5 123,184,837 A/G 43 PRDM6 Intronic QRS area, I −0.055 1.8 × 10−6
ARD rs34766086* 2 40,512,632 T/G 5.67 SLC8A1 Upstream R dur., V5 −0.085 7.1 × 10−4
EF rs2234962 10 119,670,121 C/T 24.2 BAG3 Missense R amp., V1 0.051 1.7 × 10−4
EF rs72692220* 1 50,974,791 A/G 3.15 CDKN2C Downstream Mean QRS dur. −0.13 1.8 × 10−4
EF rs35006907 8 124,847,575 A/C 35.8 ZNF572 Intergenic R amp., V1 0.042 6.0 × 10−4
LVEDD rs2234962 10 119,670,121 C/T 24.2 BAG3 Missense R amp., V1 −0.099 1.8 × 10−13
LVEDD rs397516082 11 47,346,372 C/T 0.175 MYBPC3 Splice acceptor R dur., V4 −0.57 2.3 × 10−9
LVEDD rs35006907 8 124,847,575 A/C 35.8 ZNF572 Intergenic R amp., V1 −0.058 9.7 × 10−7
LVEDD rs4794562* 17 55,302,450 T/C 25.7 HLF Intronic QRS dur., V3 −0.06 5.3 × 10−6
LVEDD rs17305149* 3 14,235,797 G/A 18.5 LSM3 Intergenic R dur., V5 0.064 1.8 × 10−5
LVEDD rs72692220* 1 50,974,791 A/G 3.15 CDKN2C Downstream Mean QRS dur. 0.14 4.0 × 10−5
LVEDD rs16866538 2 178,795,185 A/G 4.93 TTN Missense S amp., V1 −0.098 2.3 × 10−4
LVEDD rs143158900* 10 112,746,619 CA/C 17.6 VTI1A Intronic QRS p-2-p, I 0.055 2.6 × 10−4
LVEDD rs147436240 6 36,680,287 C/CGCGT 17.2 CDKN1A Intronic Mean QRS dur. −0.055 3.9 × 10−4
LVEDD rs9909004* 17 66,310,015 C/T 38.6 PRKCA Intronic QRS dur., V3 0.041 5.5 × 10−4
LVESD rs1461990* 8 107,075,400 G/C 47.5 ANGPT1 Intergenic Q amp., V6 0.07 5.8 × 10−4
LVPWT rs397516082 11 47,346,372 C/T 0.175 MYBPC3 Splice acceptor R dur., V4 0.62 4.9 × 10−11
IVST rs397516082 11 47,346,372 C/T 0.175 MYBPC3 Splice acceptor R dur., V4 1.2 1.5 × 10−37
IVST rs4284441* 12 114,924,167 T/C 36.5 TBX3 Intergenic QRS area, V6 0.047 7.2 × 10−5
IVST rs7301677* 12 114,943,342 T/C 34.8 TBX3 Intergenic VAT, V6 −0.041 5.7 × 10−4
We only show results for 5% FDR, P≤ 7.1 × 10−4. We denote unreported associations with a star. EA effect allele, OA other allele, EAF effect allele frequency, s.d. standard deviation, Dur. duration, Amp.
amplitude, ARD aortic root diameter (N= 19,513), EF ejection fraction (N= 17,109), LVEDD left ventricular end-diastolic dimension (N= 18,487), LVESD left ventricular end-systolic dimension (N=
5704), LVPWT left ventricular posterior wall thickness (N= 18,626), IVST interventricular septum thickness (N= 18,775)
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(1% FDR, Supplementary Data 11). After clustering gene sets by
similarity, the most significant gene sets related to abnormal
myocardium layer morphology, pericardial effusion, abnormal
heart morphology and the cell-substrate adherens junction. Many
genes near unreported QRS variants were part of gene sets linked
to the adherens junction, including VCL, SMTN, PXN, FHL2, SVIL
and ANKRD1. We also used DEPICT to point out genes within
each associated locus based on functional similarity to genes within
other associated loci (5% FDR, Supplementary Data 12).
Of the 190 QRS variants, 20 are intronic or coding in genes with
higher expression in heart muscle than other tissue types in the
Human Protein Atlas (total 201 genes)41. Variants in some of these
genes have been described by OMIM as causing autosomal
dominant heart conditions (MYBPC3, MYH6, MYH7, CTNNA3,
RBM20, RYR2, SCN5A) or associated in GWAS with heart diseases
(CASQ2, MYH7B, MYO18B, SYNPO2L, TBX5, TRIM63)27,42,43,
resting heart rate (CCDC141, FHOD3)44 or non-QRS ECG
parameters (ALPK3, RNF207)45,46. Other genes have not been
implicated in heart diseases (ADPRHL1, KLHL38, SH3BGR).
Given both the QRS association and the heart muscle expression,
variants in these genes could substantially affect cardiac function.
Using the prior information on expression of genes in the
heart, we searched for additional rare (MAF ≤ 1%) coding
variants that associate with the QRS complex in these 201 genes.
Thirteen additional variants associate with one or more QRS
parameters (Supplementary Data 13, P < 0.05/(number of coding
variants tested)= 2.4 × 10−5). We found four missense variants at
unreported QRS loci: C10orf71, FBXO40, GRM1 and HCN4. We
note that HCN4 is a known bradycardia gene47. We identified one
frameshift and three missense QRS variants where we had
identified non-coding QRS variants previously in our study: in
CTNNA3, NKX2-5, RNF207 and TBX5. We recently reported the
missense variant p.Phe145Leu in NKX2-5 as causing cardiomyo-
pathy and arrhythmias36.
Discussion
We used whole-genome sequence data to perform a GWAS on
the QRS complex of the 12-lead ECG in 81,192 Icelanders and
identified 130 QRS loci. We found 190 distinct QRS variants, of
which 106 are at 86 loci that have not been reported for QRS
before, and assessed their effects on seven echocardiographic
traits and 22 cardiovascular diseases.
We demonstrate an advantage of performing an in-depth
examination of the QRS complex when studying the genetic
influence on ventricular depolarisation, myocardial mass and
associated cardiac disease. Our approach yielded 130 QRS loci,
compared to 52 loci identified in a recent GWAS of the QRS
complex14 of a similar size (up to 73,518 individuals) that
assessed only the QRS duration and three voltage criteria, mea-
sures commonly used clinically. If we had exclusively tested these
same four measures, we would have identified associations at only
54 loci. Thus, additional measures of the QRS complex (the QRS
area, ventricular activation time and distinct measures of the Q, R
and S waves) yielded 76 additional loci.
Many of the 123 parameters tested are correlated, and most
variants associate with more than one. However, some variants
associate with only one QRS measure, some with only one lead.
The R amplitude is the QRS measure that captures most QRS
associations, about half of them. The R wave in lead V1 captures
half of the R amplitude associations, and 15 variants associate
only with the R amplitude in lead V1. Under normal conditions,
the R wave is small in lead V1 but gets progressively larger in the
precordial leads, usually reaching maximum amplitude in lead
V5. The small R wave in lead V1 represents the initial part of
ventricular depolarisation. Some conditions may cause an
abnormally large R wave in lead V1, including right bundle
branch block, type A Wolf–Parkinson–White Syndrome, pos-
terior myocardial infarction, right ventricular hypertrophy and
acute right ventricular dilatation48. The QRS area captures the
second highest number of associations. Although the QRS area
has not been used in a GWAS before, it improves identification of
left ventricular hypertrophy over standard voltage criteria49. The
genetic influence on various aspects of the cardiac conduction
system is both tightly linked and complex, as the majority of QRS
variants associates also with ECG measures reflecting atrial and
atrioventricular conduction, and ventricular repolarisation, but
with a variable magnitude and direction of effects.
Before our study, only two low-frequency (1% ≤MAF ≤ 5%)
and no rare variants had been shown to associate with the QRS
complex in a GWAS14. We found 33 unreported large-effect
associations with rare or low-frequency coding variants, including
13 associations identified by using a priori expression informa-
tion. This includes associations with a missense variant in
ADPRHL1 that also associates genome-wide significantly with left
anterior fascicular block, and a stop-gain variant in HMCN2 that
also associates with a high risk of left posterior fascicular block.
The rare missense variant p.Ala2397Val in FLNC associates with
a larger R amplitude in lead V1 and reduced risk of myocardial
infarction, with opposite direction of effects to those of p.
Phe1626Serfs*40, a reported frameshift variant that causes car-
diomyopathy, thus suggesting an opposite functional effect of p.
Ala2397Val36. FLNC encodes filamin C, a large actin-crosslinking
protein expressed in striated muscles. Filamin C anchors major
protein complexes at the sarcolemma, Z-discs and intercalated
discs in cardiomyocytes to the actin cytoskeleton and provides a
scaffold for a variety of cytoplasmic signalling proteins50,51.
We identified 91 associations for 57 of the QRS variants with a
spectrum of cardiovascular diseases, including arrhythmias and
conduction disorders, hypertension, ischemic disease, cardio-
myopathies, and valve diseases. We found 41 unreported asso-
ciations, including four with supraventricular tachycardia (SVT),
one of which is with a low-frequency variant located near
KCND3, a potassium channel gene that has been implicated in
Brugada syndrome52 and AF27, and is the first genome-wide
significant SVT association.
We found an association with an intronic variant in PXN,
encoding paxillin, which has not been associated with AF before.
Paxillin is expressed at focal adhesions of non-striated cells and
costameres of striated muscle cells35, and regulates cardiac
Table 3 QRS variants with parent-of-origin effects
Top QRS
parameter
Variant Chr. Pos. (hg38) EA/
OA





R dur., V4 rs11761424 7 14,414,730 A/G 35 DGKB 0.068 6.5 × 10−15 0.018 0.034 4.1 × 10−5
R amp., V1 rs116904997 12 120,230,731 A/G 1.28 PXN 0.28 7.3 × 10−13 0.073 0.062 1.6 × 10−4
We show results for Phet < 0.05/190= 2.6 × 10−4. EA effect allele, OA other allele, EAF effect allele frequency, Pat. paternal, s.d. standard deviation, Mat. maternal, Phet P value for heterogeneity in the
effect estimates between the paternal and maternal models, Dur. duration, Amp. amplitude
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contractility in the zebrafish53. The PXN variant, as well as a
variant intronic to DGKB, associates primarily with the QRS
complex when the allele is inherited paternally. These loci are not
known to be imprinted, although paxillin has been shown to
regulate expression, not imprinting, of the imprinted genes IGF2
and H19 through long-range chromosomal interactions between
the IGF2 and H19 promoters and a shared distal enhancer54.
A common variant in HLF associates with a decreased risk of
heart failure, a lower risk of CAVB and RBBB, a smaller ventricle
and a shorter QRS duration. HLF encodes a member of the
proline acidic-rich (PAR) protein family, a subset of the bZIP
transcription factors that accumulate with robust circadian
rhythms in tissues with high amplitudes of clock gene expression.
The knockout of HLF along with two other PAR bZip tran-
scription factors has been shown to lead to cardiac hypertrophy
and left ventricular dysfunction in mice55.
In summary, our results demonstrate the advantage of ana-
lysing the QRS complex in a detailed manner. The use of whole-
genome sequencing facilitates the discovery of associations with
protein-coding variants that implicate particular genes in the
biology of ventricular depolarisation and cardiac pathology. The
findings provide new insights into the complex genetics of cardiac
electrophysiology and will help direct future functional studies of
cardiovascular diseases.
Methods
Icelandic data. The ECGs were performed between 1998 and 2015 at Landspitali—
The National University Hospital, the sole tertiary care hospital in Iceland. They
were done in both inpatient and outpatient setting, using the Philips PageWriter
Trim III, Philips PageWriter 200, Philips PageWriter 50 and Philips PageWriter 70
cardiographs, and stored in the Philips TraceMasterVue ECG Management System.
We analysed ten measures of the QRS complex from 405,732 ECGs of 81,192
individuals. These ten measures were the Q, R and S wave amplitudes and durations;
QRS complex area and duration; ventricular activation time (VAT, time between the
onset of the Q wave and the peak of the R wave); and the distance from the peak of
the R wave to the nadir of the S wave (QRS peak-to-peak amplitude). We analysed
each measure for 12 ECG leads: limb leads (I–III), augmented limb leads (aVR, aVL,
aVF) and precordial leads (V1–V6). In addition, we analysed mean QRS duration
over 12 leads, the Cornell voltage criterion (for men: (R amplitude in lead aVL+ S
amplitude in lead V3) × QRS duration; for women: (R amplitude in lead aVL+ S
amplitude in lead V3+ 0.8mV) × QRS duration) and the Sokolow-Lyon voltage
criterion ((S amplitude in lead V1+ R amplitude in lead V6) × QRS duration). We
also used four phenotypes derived from automated ECG diagnoses: left anterior
fascicular block (LAFB), left bundle branch block (LBBB), left posterior fascicular
block (LPFB) and right bundle branch block (RBBB).
We used seven phenotypes describing measurements from echocardiograms:
aortic root diameter (N= 19,513), ejection fraction (N= 17,109), left ventricular
end-diastolic diameter (N= 18,487), left ventricular end-systolic diameter (N=
5,704), mitral regurgitation (N= 5,291), left ventricular posterior wall thickness
(N= 18,626) and interventricular septum thickness (N= 18,775). We obtained
these measurements from a database of 53,122 echocardiograms from 27,460
individuals, read by cardiologists at LUH between 1994 and 2015.
deCODE genetics has extensive medical information on cardiovascular diseases
for use in association analyses. The QRS variants were tested for association with
22 cardiovascular diseases: aortic valve stenosis (N= 2457), atrial fibrillation (N=
14,710), coarctation of the aorta (N= 119), complete atrioventricular block (N=
1008), congenital malformations of cardiac septa (N= 1884), coronary artery
disease (N= 38,918), dilated cardiomyopathy (N= 424), heart failure (N=
15,237), hypertension (N= 44,290), hypertrophic cardiomyopathy (N= 372),
ischemic stroke (N= 5626), mitral valve disease (N= 940), myocardial infarction
(N= 24,691), pacemaker insertion (N= 3578), patent ductus arteriosus (N= 628),
perimyocarditis (N= 971), pre-excitation Wolff-Parkinson-White syndrome (N=
275), sick sinus syndrome (N= 3568), sudden cardiac death (N= 3128),
supraventricular tachycardia (N= 1461), tetralogy of fallot (N= 60) and
ventricular tachycardia (N= 945). The sample sets were based on discharge
diagnoses from LUH from 1987 to 2017. The controls consisted of disease-free
controls (up to 380,000), randomly drawn from the Icelandic genealogical database,
and individuals from other genetic studies at deCODE.
The Icelandic Data Protection Authority and the National Bioethics Committee
of Iceland (no. VSNb2015030024/03.01 and VSNb2015030022/03.01) approved
the study.
Genotyping. In Iceland, 32.5 million sequence variants (MAF > 0.01%) were
identified by whole-genome sequencing 15,220 Icelanders using Illumina standard
TruSeq methodology to a mean depth of 35× (s.d. 8X) and imputed into 151,677
chip-typed individuals and their first- and second-degree relatives16,56. In the UK
Biobank, genotyping was performed using a custom-made Affimetrix chip (UK
BiLEVE Axiom)57 in the first 50,000 participants and Affimetrix UK Biobank
Axiom array in the remaining participants58 (95% of the signals were on both
chips). Wellcome Trust Centre for Human Genetics performed the imputation
using a combination of 1000 Genomes phase 3 (ref. 59), UK10K60 and HRC61
reference panels, for up to 92.5 million SNPs.
Statistical analysis. We adjusted quantitative traits for sex and age at measure-
ment, transformed them into a standard normal distribution using a rank-based
inverse normal transformation, and used a linear mixed model implemented by
BOLT-LMM62 to test them for association with genotypes. We used a logistic
regression model to test binary traits for association with genotypes. For the
deCODE data, we adjusted for sex, county of birth, current age or age at death
(first- and second-order terms included), blood sample availability for the indivi-
dual, and an indicator function for the overlap of the lifetime of the individual with
the timespan of phenotype collection. For the UK Biobank data, we used 40
principal components to adjust for population stratification and adjusted for age
and sex in the logistic regression model. The UK Biobank study included only
white British individuals. In each study, we used LD score regression63 to account
for inflation in test statistics due to cryptic relatedness and stratification. To
combine the deCODE and UK Biobank results, we used a fixed-effect inverse
variance method based on effect estimates and standard errors64. We used a
likelihood-ratio test to compute all P values. In conditional analyses, we tested
variants within ±1Mb from the top variant and with correlation r2 < 0.05 with the
top variant, and required the variants to be genome-wide significant after cor-
recting for the top variant in a regression model.
Genetic correlation. We estimated the genetic correlation between pairs of traits
using LD score regression (v.1.0.0)65 and pre-computed LD scores for European
populations (downloaded from https://data.broadinstitute.org/alkesgroup/LDSCORE/
eur_w_ld_chr.tar.bz2).
Depict. We used DEPICT40 to (1) prioritise candidate causal genes at associated
loci, (2) highlight enriched pathways, and (3) identify tissues/cell types where genes
at associated loci are highly expressed. DEPICT uses gene expression data derived
from a panel of 77,840 mRNA expression arrays together with 14,461 existing gene
sets based on molecular pathways derived from experimentally verified
protein–protein interactions66, genotype–phenotype relationships from the Mouse
Genetics Initiative67, Reactome pathways68, KEGG pathways69, and Gene Ontol-
ogy (GO) terms70. DEPICT reconstitutes these 14,461 gene sets by calculating for
each gene the probability of membership in each gene set, based on similarities
across the expression data. Using these membership probabilities and a set of trait-
associated loci, DEPICT tests whether any of the 14,461 reconstituted gene sets are
enriched for genes at the trait-associated loci, and prioritises genes that share
predicted functions with genes at other trait-associated loci. Additionally, DEPICT
uses 37,427 human mRNA microarrays to search for tissues/cell types in which
genes from associated loci are highly expressed (all genes harbouring variants in LD
of r2 > 0.5 from the most significant variant). We ran DEPICT using all QRS-
associated variants. We also used DEPICT to compute pairwise Pearson correla-
tions between all reconstituted gene sets and clustered them by similarity using the
Affinity Propagation method71.
Reporting summary. Further information on research design is available in
the Nature Research Reporting Summary linked to this article.
Data availability
The Icelandic population WGS data has been deposited at the European Variant Archive
under accession code PRJEB8636. The GWAS summary statistics are available at https://
www.decode.com/summarydata. The data supporting the findings of this study are
available within the article, its Supplementary Data files and upon request. The UK
Biobank data can be obtained upon application (ukbiobank.ac.uk).
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